A phase I/II study of weekly paclitaxel therapy for metastatic gastric cancer (Step 2)
Phase 2
- Conditions
- Fluoropyrimidine failure metastatic gastric cancer
- Registration Number
- JPRN-C000000101
- Lead Sponsor
- Hiroshima Cancer Therapy Development Organization (HiCTDO)
- Brief Summary
Paper is being prepared (Sep. 1/2008)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
(1)With other serious disease: Ischemic heart disease, arrhythmia, Myocardiac infarction occurred within 6 month,Liver cirrhosis, Hemorrhage/bleeding>=grade3(NCI-CTC),Symptomatic psychological disease, Uncontrollable diabetes, Obstructive bowel disease (2)Active secondary cancer (3)A past history of drug allergy (4)A past history of allergic reaction to polyoxy-ethilen oil (5)Prior chemotherapy including a taxane (6)Peripheral neuropathy>=grade 2 in prior chemotherapy (7)Pregnancy or breast feeding (8)Ineligible decision by principal investigator (9)Active hepatitis or syphilis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method